ASP-7962
- Generic Name
- ASP-7962
A Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the Knee
Phase 2
Completed
- Conditions
- Osteoarthritis of the KneeChronic Lower Back Pain
- Interventions
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 215
- Registration Number
- NCT02611466
- Locations
- ðŸ‡ðŸ‡º
Site HU36002, Baja, Hungary
🇨🇿Site CZ42006, Hradec Kralove, Czechia
🇧🇪Site BE32003, Leuven, Belgium
A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Multiple Ascending Doses of ASP7962 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy VolunteersPharmacokinetics of ASP7962
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-05-13
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 48
- Registration Number
- NCT02136316
- Locations
- 🇬🇧
Site GB44001 Parexel Early Phase Clinical Unit, London, United Kingdom
A Clinical Trial to Investigate Safety and Tolerability of ASP7962 in Healthy Humans
Phase 1
Completed
- Conditions
- SafetyPharmacokinetics of ASP7962Tolerability
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 48
- Registration Number
- NCT01981928
- Locations
- 🇬🇧
Parexel Early Phase Clinical Unit London, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath